Today, a new generation of innovative biomedical startups continue to win billion-dollar valuations and massive infusions of venture capital as they promise to revolutionize medicine and disrupt massive healthcare markets. According to a new January paper authored by three Stanford researchers, many of these companies also publish little to no peer-reviewed research.
Last April, Facebook CEO Mark Zuckerberg sat, sweating, before a Congressional panel. Under scrutiny was how a British political consulting firm had gained access to the private data of more than 50 million Facebook users while, in the meantime, Russian operatives leveraged the platform as a tool to interfere in the election of a U.S. president.
Theranos was one of a handful of so-called “unicorns,” a Silicon Valley term for startup companies with a valuation of at least $1 billion.
On Feb. 23, Stanford filed a federal lawsuit against multiple Hewlett-Packard companies, seeking millions in damages for HP’s purported chemical contamination of “substantial portions” of 1601 S. California Avenue — land that Stanford owns — during a grading project sometime between 1970 and 1999. The named corporations in the original lawsuit are Hewlett-Packard Company and Hewlett Packard Enterprise (HPE) and Agilent Technologies.
For some Stanford startup founders, “anti-establishment” and privilege go hand in hand.